vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.8%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 10.6%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DOCS vs ESPR — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $168.4M |
| Net Profit | $61.6M | — |
| Gross Margin | 89.9% | — |
| Operating Margin | 38.9% | 50.6% |
| Net Margin | 33.3% | — |
| Revenue YoY | 9.8% | 143.7% |
| Net Profit YoY | -18.1% | — |
| EPS (diluted) | $0.31 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $168.4M | ||
| Q3 25 | $168.5M | $87.3M | ||
| Q2 25 | $145.9M | $82.4M | ||
| Q1 25 | $138.3M | $65.0M | ||
| Q4 24 | $168.6M | $69.1M | ||
| Q3 24 | $136.8M | $51.6M | ||
| Q2 24 | $126.7M | $73.8M | ||
| Q1 24 | $118.1M | $137.7M |
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $-31.3M | ||
| Q2 25 | $53.3M | $-12.7M | ||
| Q1 25 | $62.5M | $-40.5M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-29.5M | ||
| Q2 24 | $41.4M | $-61.9M | ||
| Q1 24 | $40.6M | $61.0M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | 50.6% | ||
| Q3 25 | 37.8% | -11.4% | ||
| Q2 25 | 37.4% | 8.6% | ||
| Q1 25 | 35.2% | -34.0% | ||
| Q4 24 | 47.4% | -6.4% | ||
| Q3 24 | 38.8% | -31.0% | ||
| Q2 24 | 36.4% | 3.5% | ||
| Q1 24 | 35.5% | 52.5% |
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | -35.9% | ||
| Q2 25 | 36.5% | -15.4% | ||
| Q1 25 | 45.2% | -62.2% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -57.2% | ||
| Q2 24 | 32.7% | -83.9% | ||
| Q1 24 | 34.4% | 44.3% |
| Q4 25 | $0.31 | $0.32 | ||
| Q3 25 | $0.31 | $-0.16 | ||
| Q2 25 | $0.27 | $-0.06 | ||
| Q1 25 | $0.31 | $-0.21 | ||
| Q4 24 | $0.37 | $-0.14 | ||
| Q3 24 | $0.22 | $-0.15 | ||
| Q2 24 | $0.21 | $-0.33 | ||
| Q1 24 | $0.20 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $-302.0M |
| Total Assets | $1.2B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $167.9M | ||
| Q3 25 | $169.2M | $92.4M | ||
| Q2 25 | $137.3M | $86.1M | ||
| Q1 25 | $209.6M | $114.6M | ||
| Q4 24 | $165.3M | $144.8M | ||
| Q3 24 | $184.2M | $144.7M | ||
| Q2 24 | $111.4M | $189.3M | ||
| Q1 24 | $96.8M | $226.6M |
| Q4 25 | $979.3M | $-302.0M | ||
| Q3 25 | $1.1B | $-451.4M | ||
| Q2 25 | $1.0B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.0B | $-388.7M | ||
| Q3 24 | $961.2M | $-370.2M | ||
| Q2 24 | $913.6M | $-344.2M | ||
| Q1 24 | $901.4M | $-294.3M |
| Q4 25 | $1.2B | $465.9M | ||
| Q3 25 | $1.3B | $364.0M | ||
| Q2 25 | $1.2B | $347.1M | ||
| Q1 25 | $1.3B | $324.0M | ||
| Q4 24 | $1.2B | $343.8M | ||
| Q3 24 | $1.1B | $314.1M | ||
| Q2 24 | $1.1B | $352.3M | ||
| Q1 24 | $1.1B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $45.2M | ||
| Q3 25 | $93.9M | $-4.3M | ||
| Q2 25 | $62.1M | $-31.4M | ||
| Q1 25 | $98.5M | $-22.6M | ||
| Q4 24 | $65.2M | $-35.0M | ||
| Q3 24 | $68.3M | $-35.3M | ||
| Q2 24 | $41.2M | $-7.2M | ||
| Q1 24 | $63.9M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.0% | 0.1% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
